查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1943414

Montelukast sodium市场依剂型、剂量、用途及通路划分，全球预测（2026-2032）

Montelukast Sodium Market by Formulation, Dosage Strength, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年Montelukast sodium市场价值为 4.5912 亿美元，预计到 2026 年将成长至 4.9096 亿美元，预计到 2032 年将达到 7.4037 亿美元，复合年增长率为 7.06%。

关键市场统计数据
基准年 2025 4.5912亿美元
预计年份：2026年 4.9096亿美元
预测年份 2032 7.4037亿美元
复合年增长率 (%) 7.06%

Montelukast sodium的策略性应用：面向知情决策者的临床效用、法规环境和以病人为中心的意义框架

Montelukast sodium是一种口服白三烯受体拮抗剂，在呼吸系统和过敏性疾病的治疗中占据着独特的地位，并拥有悠久的临床效用历史。其治疗范围涵盖儿童到成人，能够有效抑制气喘和过敏性鼻炎相关的发炎通路，同时每日一次的给药方案也满足了患者的依从性需求。临床医生高度重视其便利性、良好的耐受性以及在特定患者群体中作为单药治疗和辅助性治疗的效用，这些临床特性持续影响着不同医疗机构的治疗流程。

临床证据、监管审查和分销动态方面的变革性发展正在重塑Montelukast sodium的竞争格局和业务运营。

Montelukast sodium的市场格局正受到科学、监管和商业性因素的多重影响而重塑，相关人员的期望和营运重点也随之改变。药物警戒技术的进步和大规模真实世界证据的积累，使得安全信号受到更严格的审查，并促使处方医生和患者之间进行更深入的风险获益讨论。同时，生物目标和先进吸入控制药物的出现，正在改变治疗格局，重塑特异性通路治疗方案，并引发关于现有口服药物重新定位的讨论。

美国关税调整至2025年如何引发策略采购变化与供应链调整，进而影响Montelukast sodium的取得与分销动态？

国际贸易和海关制度的政策趋势，特别是美国在2025年前实施的措施，正对原料原料药和製剂的供应链成本、筹资策略和采购决策产生重大影响。关税差异和日益复杂的进口合规流程迫使製造商和经销商重新评估製造地、供应商冗余和海关优化策略。这些调整并非只是贸易问题；它们还会影响整个供应商网路的库存管理实务、前置作业时间缓衝和合约条款。

透过对製剂形式、剂量强度、临床用途和分销管道进行详细的細項分析，制定产品定位、生产製造和通路拓展策略。

强大的細項分析揭示了Montelukast sodium在製剂形式、剂量强度、给药方法和分销管道等方面的不同临床、商业性和营运影响。就製剂形式而言，咀嚼锭、口服颗粒剂和一般锭剂在患者遵从性和生产方面各有不同。咀嚼片和口服颗粒剂尤其适用于儿童患者群体，需要专门的策略来确保其稳定性和偏好，而普通片剂则更注重成本效益和已确立的成人剂量。在这些剂型之间转换时，需要仔细选择辅料、包装设计以及与患者沟通，以维持治疗效果。

美洲、欧洲、中东和非洲以及亚太地区特有的临床、监管和分销趋势正在影响药物准入和商业化策略。

在美洲、欧洲、中东和非洲以及亚太地区，区域差异对Montelukast sodium的临床实践模式、监管预期和分销模式的形成起着至关重要的作用。在美洲，医疗保健系统支付方趋势各异，且都注重成本效益和病患依从性。在都市区和综合医疗网络中，处方集管理和基于价值的合约受到重视，而社区药房仍然是门诊病人获取药物的核心管道。监管机构和专业协会会影响附加檔的内容和安全建议，进而影响处方医师的信心和病人的接受度。

製造商、契约製造製造商、经销商和数位健康合作伙伴如何影响Montelukast sodium的生产可靠性、分销管道的履行以及临床应用。

製造商、合约研究组织、专科经销商和药房网路之间的竞争与合作动态影响着Montelukast sodium的生产、供应和市场定位。拥有现有药品组合的成熟製药公司透过整合通路策略来推广该产品，优先发展药物监测基础设施并建立与临床医生的长期合作关係。他们的投资往往集中在标籤管理、儿童製剂支援以及广泛的教育和宣传活动上，以维持处方医生和患者的信任。

为生产商和通路合作伙伴提供优先的实用建议，以加强药物警戒、提高供应链韧性并推动以患者为中心的Montelukast sodium商业化。

药物研发、分销和临床倡导领域的领导者应采取多管齐下的策略，使产品管理与现代供应链的实际情况和不断变化的临床预期相契合。首先，应投资健全的药物监测计画和透明的安全沟通，以维持处方医师的信心并支持合理的治疗用药。这些努力应与临床医生教育相结合，阐明Montelukast在目前治疗流程中的作用，并确定可能受益的患者群体。

本文描述了用于得出有关Montelukast sodium的临床和操作性可操作结论的证据来源、专家咨询和分析方法。

本分析所依据的研究综合了多方面的证据，以确保观点平衡且切实可行。主要资讯来源包括对临床专家、药房主任和供应链经理的访谈，以了解医疗专业人员的观点和营运限制。二级资讯来源包括监管指导文件、同行评审的临床文献和政策声明，以深入了解安全性、治疗定位和区域监管趋势。此外，还查阅了贸易和海关出版物，以了解与供应链规划相关的关税和采购考量。

总结性分析强调了协作式药物监测、供应链灵活性以及基于证据的商业策略对于Montelukast sodium的重要性。

总之，儘管Montelukast sodium在呼吸系统和过敏性疾病的治疗中仍具有临床价值，但其持续效用取决于严密的安全管理、灵活的供应策略和精准的临床定位。不断变化的药物警戒预期、治疗方案的更新换代以及分销管道的创新，都要求相关人员积极主动地收集证据、优化通路并与监管机构保持沟通。那些能够将临床讯息与营运韧性相结合，并投资于有针对性的真实世界研究的机构，将更有能力有效地支持临床医生和患者。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Montelukast sodium市场以剂型划分

  • 咀嚼片
  • 口服颗粒剂
  • 药片

第九章Montelukast sodium市场：依剂量划分

  • 10mg
  • 4mg
  • 5mg

第十章Montelukast sodium市场：依应用领域划分

  • 过敏性鼻炎
  • 气喘
  • 运动诱发支气管收缩

第十一章Montelukast sodium市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章Montelukast sodium市场区域概览

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Montelukast sodium市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国Montelukast sodium市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国：Montelukast sodium市场

16. 中国：Montelukast sodium市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Jubilant Generics Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-F847BD9C7293

The Montelukast Sodium Market was valued at USD 459.12 million in 2025 and is projected to grow to USD 490.96 million in 2026, with a CAGR of 7.06%, reaching USD 740.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.12 million
Estimated Year [2026] USD 490.96 million
Forecast Year [2032] USD 740.37 million
CAGR (%) 7.06%

A strategic introduction to montelukast sodium that frames clinical utility, regulatory context, and patient-centered implications for informed decision-makers

Montelukast sodium occupies a distinct position in respiratory and allergic disease management as an oral leukotriene receptor antagonist with long-standing clinical utility. Its role spans pediatric and adult therapeutic paradigms, offering once-daily dosing that aligns with adherence needs while addressing inflammatory pathways implicated in asthma and allergic rhinitis. Clinicians value its convenience, tolerability profile, and utility as both monotherapy and adjunctive therapy in specific patient cohorts, and these clinical characteristics continue to shape treatment algorithms across care settings.

From a regulatory perspective, montelukast has traversed decades of post-market surveillance and label refinements, prompting careful risk-benefit assessments that influence prescriber behavior and patient counseling. Concurrently, improvements in patient education, electronic prescribing, and adherence-support tools have altered how montelukast is deployed in practice, with a growing emphasis on shared decision-making and individualized therapy selection. As stakeholders converge around quality, safety, and real-world performance, strategic planning must account for evolving clinical evidence, safety communications, and the broader therapeutic landscape that includes biologics, inhaled controllers, and digital health adjuncts.

Looking ahead, the intersection of established clinical utility and dynamic health system priorities requires a holistic vantage point. Commercial strategies must be informed by payer requirements, formulary placement dynamics, and channel preferences, while clinical strategies should reflect updated safety guidance and patient-centric delivery models. In short, a multidimensional understanding of montelukast's role is essential for organizations seeking to preserve therapeutic value and optimize patient outcomes within contemporary healthcare ecosystems.

Transformative developments in clinical evidence, regulatory scrutiny, and distribution dynamics that are reshaping montelukast sodium's competitive and operational landscape

The landscape surrounding montelukast sodium has been reshaped by a confluence of scientific, regulatory, and commercial shifts that are redefining stakeholder expectations and operational priorities. Advances in pharmacovigilance and large-scale real-world evidence generation have heightened scrutiny on safety signals, prompting more nuanced benefit-risk discussions with prescribers and patients. At the same time, the therapeutic ecosystem has evolved with targeted biologic therapies and advanced inhaled controllers, which are reconfiguring pathway-specific treatment choices and compelling repositioning conversations for older oral agents.

Parallel to therapeutic evolution, supply chain resilience and cost containment pressures have elevated the importance of distribution agility and channel optimization. Digital transformation in healthcare - from telemedicine-enabled prescribing to e-pharmacy growth - is changing how patients access chronic respiratory therapies and how manufacturers engage with payers and providers. Moreover, regulatory authorities worldwide are increasingly harmonizing post-market surveillance expectations while demanding greater transparency around adverse event communication, which influences label updates and promotional approaches.

Consequently, commercial models must adapt by combining rigorous safety stewardship with targeted clinical positioning that highlights appropriate patient subsets and complementary roles alongside newer therapeutics. Strategic differentiation will come from evidence-driven engagement, more granular segmentation of patient needs, and an integrated approach to channel and stakeholder management that anticipates regulatory shifts and leverages emerging distribution pathways to preserve therapeutic relevance.

How U.S. tariff adjustments through 2025 triggered strategic sourcing changes and supply chain adaptations that influence access and distribution dynamics for montelukast sodium

Policy developments in international trade and tariff regimes, including measures implemented by the United States through 2025, have exerted a meaningful influence on supply chain costs, procurement strategies, and sourcing decisions for active pharmaceutical ingredients and finished dose forms. Tariff differentials and import compliance complexities have prompted manufacturers and distributors to reassess manufacturing footprints, supplier redundancy, and customs optimization strategies. These adjustments are not merely transactional; they affect inventory management practices, lead-time buffers, and contractual terms across the supplier network.

Consequently, companies procuring raw materials or finished product for distribution within U.S. channels have placed greater emphasis on nearshoring, supplier concentration risk reduction, and alternative logistics models to mitigate tariff-driven cost exposure. In parallel, procurement teams have strengthened customs and trade compliance functions to minimize unexpected duties and to leverage tariff classifications and free trade agreements where applicable. These operational shifts have been accompanied by more conservative inventory postures in some organizations and increased collaboration with third-party logistics providers to maintain service levels while controlling landed costs.

Moreover, the ripple effects extend to channel partners and downstream stakeholders; hospital pharmacies, retail networks, and online pharmacy platforms have adjusted replenishment strategies and contract negotiations to reflect altered supplier economics. In response, manufacturers and distributors are prioritizing transparent commercial terms and flexible supply arrangements to sustain access across clinical settings. In sum, the tariff environment through 2025 has accelerated structural supply chain adaptations and elevated the strategic importance of trade-aware sourcing and distribution planning within the montelukast sodium value chain.

Deep segmentation analysis across formulation, strength, clinical application, and distribution channel to inform product positioning, manufacturing, and channel engagement strategies

A robust segmentation lens reveals differentiated clinical, commercial, and operational implications for montelukast sodium when framed by formulation, dosage strength, application, and distribution channel. When considering formulation, chewable tablet, oral granules, and conventional tablet presentations each present distinct patient adherence profiles and manufacturing considerations; chewable tablets and oral granules are particularly relevant to pediatric populations and require tailored stability and palatability strategies, whereas standard tablets emphasize cost-efficient production and established adult dosing practices. Transitioning between these formats demands attention to excipient selection, packaging design, and patient counseling to preserve therapeutic fidelity.

Dosage strength segmentation across 10mg, 4mg, and 5mg highlights dosing flexibility and the need for clear prescribing guidance. The availability of multiple strengths supports dose optimization across age groups and clinical scenarios, but it also introduces complexity in inventory management and clinician decision-making. Closely aligned with this are application-based distinctions: allergic rhinitis, asthma, and exercise-induced bronchoconstriction each present unique clinical pathways and stakeholder touchpoints. For example, allergic rhinitis often involves primary care and otolaryngology pathways with emphasis on symptomatic relief and seasonal management, while asthma care tends to involve respiratory specialists and integrated care teams with a focus on exacerbation prevention and long-term control.

Channel dynamics further nuance these considerations; hospital pharmacies, online pharmacies, and retail pharmacies each impose different fulfillment expectations, regulatory interactions, and patient service models. Hospital pharmacies often emphasize formulary alignment and inpatient continuity of care, retail pharmacies prioritize OTC-adjacent counseling and front-line dispensing efficiency, and online pharmacies drive considerations around digital patient engagement and remote adherence support. Taken together, these segmentation axes inform product development priorities, packaging and labeling strategies, and go-to-market approaches that align clinical value propositions with the operational realities of each distribution route.

Region-specific clinical, regulatory, and distribution dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access and commercialization strategies

Regional nuances play a pivotal role in shaping clinical practice patterns, regulatory expectations, and distribution models for montelukast sodium across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems exhibit varied payer dynamics and a strong focus on cost-effectiveness and adherence; urban and integrated health networks emphasize formulary management and value-based contracting, while community pharmacies remain central to outpatient access. Governing authorities and professional societies influence label communication and safety advisories, which in turn influence prescriber confidence and patient acceptance.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement pathways vary significantly, prompting differentiated approaches to evidence generation and market access engagement. Health technology assessment processes and national formulary committees often require robust safety and comparative effectiveness narratives, and regional procurement practices can favor pooled purchasing arrangements that necessitate flexible contracting. In certain markets, supply chain fragility and import dependency require contingency planning and localized distribution partnerships to maintain continuity.

In the Asia-Pacific region, rapid urbanization, expanding primary care networks, and rising digital health adoption are reshaping how chronic respiratory therapies are prescribed and dispensed. Local manufacturing capacity and regulatory pathways can differ materially between jurisdictions, and country-specific labeling or pediatric formulation preferences may drive localized product adaptations. Across all regions, evolving pharmacovigilance expectations and the increased availability of real-world evidence necessitate harmonized safety messaging and adaptive commercialization models that respect regional regulatory norms while preserving consistent clinical positioning.

How manufacturers, contract producers, distributors, and digital health partners are influencing production reliability, channel fulfillment, and clinical engagement for montelukast sodium

Competitive and collaborative dynamics among manufacturers, contract development organizations, specialty distributors, and pharmacy networks influence how montelukast sodium is produced, supplied, and positioned. Established pharmaceutical firms with legacy portfolios approach the product through integrated channel strategies, prioritizing pharmacovigilance infrastructure and long-term clinician relationships. Their investments tend to focus on label stewardship, pediatric formulation support, and broad-based educational outreach to preserve trust among prescribers and patients.

Manufacturers with contract manufacturing or outsourcing models emphasize supply reliability and cost efficiency, leveraging strategic partnerships to manage API sourcing and finished-dose production. These relationships are increasingly governed by quality agreements that incorporate traceability, change management protocols, and contingency sourcing plans to mitigate supplier disruptions. At the distribution level, specialty wholesalers and pharmacy chains vary in their expectations around lead times, rebates, and inventory commitments, which shapes commercial terms and fulfillment approaches.

Additionally, digital health providers and online pharmacy platforms are emerging as influential channel partners that extend patient engagement beyond dispensing. Their capacity to offer adherence programs, remote monitoring, and telemedicine integration creates differentiated value propositions for stakeholders seeking to optimize long-term outcomes. Cross-sector collaborations - for example, between clinical specialty societies, patient advocacy groups, and manufacturers - can amplify safety communication and education efforts, improving appropriate use and aligning stakeholders around evidence-informed practice.

Practical and prioritized recommendations for manufacturers and channel partners to enhance pharmacovigilance, supply resilience, and patient-centered commercialization for montelukast sodium

Leaders across pharmaceutical development, distribution, and clinical advocacy should adopt a multi-pronged strategy that aligns product stewardship with contemporary supply chain realities and evolving clinical expectations. First, invest in robust pharmacovigilance programs and transparent safety communication to maintain prescriber trust and to support appropriate therapeutic use. These efforts should be paired with clinician-facing education that clarifies the role of montelukast within current treatment algorithms and identifies patient cohorts most likely to derive benefit.

Second, strengthen supply chain resilience by diversifying API and finished dose suppliers, exploring regional manufacturing options, and formalizing contingency plans that address tariff-induced cost volatility and logistics disruptions. Procurement functions should collaborate closely with regulatory and quality teams to ensure continuity without compromising compliance. Third, tailor channel strategies to meet the distinct requirements of hospital pharmacies, retail networks, and online platforms; invest in packaging, patient information, and digital adherence tools that reflect the needs of pediatric and adult patient segments respectively.

Finally, pursue targeted real-world evidence initiatives and collaborative research that illuminate comparative effectiveness and long-term safety in diverse patient populations. Use these insights to inform payer dialogues and to support value propositions that resonate with formulary decision-makers and clinicians. Together, these actions create a defensible, patient-centered commercial approach that balances safety stewardship, operational resilience, and demonstrable clinical value.

Description of the evidence sources, expert engagements, and analytical techniques used to derive clinically and operationally actionable insights for montelukast sodium

The research underpinning this analysis integrated multiple evidence streams to ensure a balanced, actionable perspective. Primary inputs included interviews with clinical specialists, pharmacy directors, and supply chain leaders to capture practitioner viewpoints and operational constraints. Secondary sources comprised regulatory guidance documents, peer-reviewed clinical literature, and policy statements that informed safety, therapeutic positioning, and regional regulatory dynamics. Trade and customs publications were examined to contextualize tariff and sourcing considerations relevant to supply chain planning.

Analytical methods combined qualitative synthesis with scenario-based supply chain assessment to identify structural vulnerabilities and potential mitigants. Expert validation rounds were conducted to test key interpretations and to refine practical recommendations, ensuring that proposed actions are operationally feasible and clinically appropriate. Throughout, care was taken to triangulate findings across independent sources to minimize bias and to reflect current professional practice and policy environments.

Limitations of the approach are acknowledged; while the methodology sought breadth and depth, evolving regulatory communications and dynamic trade conditions necessitate periodic updates to maintain relevance. Nonetheless, the combination of expert interviews, regulatory analysis, and supply chain scenario planning offers a rigorous foundation for strategic decision-making in clinical, commercial, and operational domains.

Conclusive synthesis emphasizing the importance of coordinated pharmacovigilance, supply chain agility, and evidence-driven commercial strategies for montelukast sodium

In closing, montelukast sodium remains a clinically valuable therapeutic option within respiratory and allergic disease management, but its continued relevance depends on vigilant safety stewardship, adaptive supply strategies, and focused clinical positioning. The interplay of evolving pharmacovigilance expectations, shifting therapeutic alternatives, and distribution innovations requires stakeholders to act proactively across evidence generation, channel optimization, and regulatory engagement. Organizations that align clinical messaging with operational resilience and that invest in targeted real-world research will be best positioned to support clinicians and patients effectively.

Strategic emphasis on pediatric formulations and patient-centric delivery, combined with nimble procurement and trade-aware sourcing, can preserve access and adherence across care settings. Moreover, constructive collaboration among manufacturers, distributors, clinicians, and digital health partners can amplify safety communication and foster practical adherence solutions. Ultimately, a coordinated and evidence-driven approach will enable healthcare and commercial stakeholders to preserve therapeutic value and to meet patient needs in a complex and evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Montelukast Sodium Market, by Formulation

  • 8.1. Chewable Tablet
  • 8.2. Oral Granules
  • 8.3. Tablet

9. Montelukast Sodium Market, by Dosage Strength

  • 9.1. 10mg
  • 9.2. 4mg
  • 9.3. 5mg

10. Montelukast Sodium Market, by Application

  • 10.1. Allergic Rhinitis
  • 10.2. Asthma
  • 10.3. Exercise-Induced Bronchoconstriction

11. Montelukast Sodium Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Montelukast Sodium Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Montelukast Sodium Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Montelukast Sodium Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Montelukast Sodium Market

16. China Montelukast Sodium Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alembic Pharmaceuticals Limited
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc.
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. Hetero Drugs Limited
  • 17.13. Jubilant Generics Limited
  • 17.14. Lupin Limited
  • 17.15. Merck & Co., Inc.
  • 17.16. Mylan N.V.
  • 17.17. Sun Pharmaceutical Industries Ltd.
  • 17.18. Teva Pharmaceutical Industries Ltd.
  • 17.19. Torrent Pharmaceuticals Ltd.
  • 17.20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONTELUKAST SODIUM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONTELUKAST SODIUM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. GCC MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 92. GCC MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. G7 MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. G7 MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. NATO MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. NATO MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)